Key Highlights

  • Onconetix (NASDAQ:ONCO) was trading up 32.24% at USD 7.26 on Friday, November 6, 2026, according to the screener, with no company announcement for the day found.
  • The company agreed in February 2026 to buy 100% of humanoid robot maker Realbotix in an all-stock share exchange, with closing targeted for the second half of 2026.
  • A 1-for-5 reverse split took effect on March 25, 2026, and the October 22 close of USD 0.41 sat near a 52-week low of USD 0.38.
  • The 52-week range ran from USD 0.38 to USD 200.00, and a published page put the Market Value near USD 1.78 million at the October 22 price.

A 32.24% Move Without a Dated Announcement

Onconetix (NASDAQ:ONCO) was trading up 32.24% at USD 7.26 on Friday, November 6, 2026, according to the screener. No company release or filing dated November 3 to November 6, 2026 that explains the move was found. The screener implies a prior close near USD 5.49 (calculated). That is far above the USD 0.41 close reported for October 22, 2026, which points to a further reverse split or share adjustment that could not be verified, so the price history should be treated with care. Investors comparing today's quote with earlier prices may be looking at figures on different share bases.

The Realbotix Share Exchange and Bridge Financing

The story behind the stock is its pending purchase of Realbotix, a maker of AI-powered humanoid robots. Onconetix signed a definitive share exchange agreement in mid-February 2026 to acquire 100% of Realbotix in an all-stock deal. Realbotix holders are expected to own a large majority of the combined company on a fully diluted basis, with the exact share depending on Onconetix's net cash at closing. Closing is targeted for the second half of 2026. In September 2026 Onconetix provided Bridge Financing to Realbotix to support the pending acquisition, and a separate release on September 24 said an Investment firm, SRX Global, had added a position in Onconetix. Realbotix also reported a Vinci AI vision system delivery to Ericsson in April, and a European telecom pilot using humanoid robots at live events in September. These are operating signs at the target, not results at Onconetix itself, and no Revenue figures for the combined company were found.

Dilution, Listing Notices and Why Moves Can Reverse

An all-stock deal means current holders could end up with a small slice of the merged company, and the final ownership split was not disclosed in the material reviewed. Company filings also include several notices of delisting or failure to satisfy a listing rule, though their dates and details were not confirmed here. Delisting risk matters for an all-stock deal, because the combined company would need to keep its listing to give Realbotix holders a tradable security. The stock fell about 37.8% over two weeks and about 99.8% over one year as of October 22, according to a published market data page. With a market value in the low millions, a small number of trades can move the price, spreads can be wide and quoted moves can reverse.

Where Things Stand

The 32.24% gain is not tied to any dated announcement that was found. Onconetix (NASDAQ:ONCO) is moving from a small drug-related Business toward humanoid robotics through a pending all-stock Realbotix deal, and speculation around that deal has driven earlier spikes. The risks are heavy dilution, listing compliance, reverse splits that distort the price history and thin trading. What to watch next is the closing date of the Realbotix transaction, any new financing and any Nasdaq correspondence.